Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Fritsch

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 31, 2016
Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitorsRobin A Fairhurst, Giorgio Caravatti, Vito Guagnano, et al.
Bioorganic & Medicinal Chemistry Letters|July 25, 2015
Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitorsRobin A Fairhurst, Patricia Imbach-Weese, Marc Gerspacher, et al.
Bioorganic & Medicinal Chemistry Letters|June 4, 2013
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluationPascal Furet, Vito Guagnano, Robin A Fairhurst, et al.
The Journal of Clinical Investigation|February 27, 2014
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110αKira Gritsman, Haluk Yuzugullu, Thanh Von, et al.
Molecular Cancer Therapeutics|July 9, 2008
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activitySauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2015
Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitorsRobin A Fairhurst, Marc Gerspacher, Patricia Imbach-Weese, et al.
Cell Reports. Medicine|April 12, 2023
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancerPriska Auf der Maur, Marcel P Trefny, Zora Baumann, et al.
Molecular Cancer Therapeutics|June 2, 2012
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrationsSaskia M Brachmann, Julia Kleylein-Sohn, Swann Gaulis, et al.
Molecular Cancer Therapeutics|December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorSauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.
Molecular Cancer Therapeutics|March 11, 2014
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trialsChristine Fritsch, Alan Huang, Christian Chatenay-Rivauday, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|August 31, 2016
Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitorsRobin A Fairhurst, Giorgio Caravatti, Vito Guagnano, et al.
Bioorganic & Medicinal Chemistry Letters|July 25, 2015
Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitorsRobin A Fairhurst, Patricia Imbach-Weese, Marc Gerspacher, et al.
Bioorganic & Medicinal Chemistry Letters|June 4, 2013
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluationPascal Furet, Vito Guagnano, Robin A Fairhurst, et al.
The Journal of Clinical Investigation|February 27, 2014
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110αKira Gritsman, Haluk Yuzugullu, Thanh Von, et al.
Molecular Cancer Therapeutics|July 9, 2008
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activitySauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2015
Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitorsRobin A Fairhurst, Marc Gerspacher, Patricia Imbach-Weese, et al.
Cell Reports. Medicine|April 12, 2023
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancerPriska Auf der Maur, Marcel P Trefny, Zora Baumann, et al.
Molecular Cancer Therapeutics|June 2, 2012
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrationsSaskia M Brachmann, Julia Kleylein-Sohn, Swann Gaulis, et al.
Molecular Cancer Therapeutics|December 23, 2011
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitorSauveur-Michel Maira, Sabina Pecchi, Alan Huang, et al.
Molecular Cancer Therapeutics|March 11, 2014
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trialsChristine Fritsch, Alan Huang, Christian Chatenay-Rivauday, et al.
Pageof 3